Peripheral effects Via the AMY2 and AMY3 receptors Cagrilintide acts peripherally: Slowing of gastric emptying , stronger than with GLP-1 Suppression of postprandial glucagon , helps control postprandial glycemic spikes Modulation of bone remodeling (via AMY3), a neutral effect, but clinically monitored Synergy with GLP-1 (the mechanistic basis of CagriSema) The main innovation is the complementarity with the GLP-1 pathway : GLP-1 suppresses appetite via the arcuate nucleus of the hypothalamus (POMC neurons, AgRP/NPY inhibition) Amylin suppresses appetite via the area postrema (CGRP-like neurons) Two independent centers, two independent mechanisms
Strong preparation habits support safer research handling across clinical environments
It engages the same amylin/calcitonin receptors in the same hindbrain area postrema as native amylin and pramlintide, 5 11 and it drives the same vagally mediated slowing of the stomach that Samsom and colleagues quantified for pramlintide
Nasal administration offers an easy, non-invasive option for consistent use, making it ideal for active individuals focused on recovery, resilience, and performance